DataMeds AI Licenses U.S. Rights to Reboot Health AI's Direct-to-Consumer GLP-1 Weight Management Platform
DataMeds AI, Inc. (NASDAQ: MEDS) entered into an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. for U.S. direct-to-consumer rights to REBOOT's proprietary GLP-1 weight management care platform. The platform will be integrated into DataMeds' Health Lives Here mobile application as a subscription-based offering. REBOOT is an operating subsidiary of Data Health Partners, Inc., and the licensed IP includes six issued patents and six patent-pending applications. No transaction...
Key takeaways
Agreement is an exclusive U.S. license, revenue sharing and marketing deal with REBOOT Health AI, Inc., a subsidiary of Data Health Partners, Inc.
Licensed IP covers six issued patents and six patent-pending applications related to data-driven outcome optimization and AI-enhanced chronic disease management.
Platform will be integrated into DataMeds' Health Lives Here mobile app (available on iOS and Android) and offered on a monthly subscription basis.
DataMeds expects the platform to drive revenue from subscriptions, pharmacy dispensing, nutraceutical sales, diagnostic lab testing and physician services.
Corexa Health's pharmacy is licensed to dispense and distribute FDA-approved GLP-1 receptor agonist drugs; Tollo Health will build targeted nutritional support programs.
Data Health Partners is currently in litigation with Teladoc Health regarding the licensed IP (Data Health Partners, Inc. v. Teladoc Health, Inc.).
No transaction value, upfront consideration, or revenue share percentages were disclosed; REBOOT technology was developed over 10 years at a stated $8 million historical cost.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MEDS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.